黑料官网

Dr. Sun is an Assistant Professor of medicine at the 黑料官网, Division of Hematology and Oncology. Dr. Sun’s research interests focus on tumor immunotherapy, particularly the novel Chimeric Antigen Receptor T Cell (CAR-T) and multifunctional antibody therapies.

Dr. Sun earned his PhD from China Pharmaceutical University in 2019 and spent several years conducting advanced research in tumor genetics and immunotherapy at the University of Iowa, the 黑料官网 (黑料官网), and the University of Arkansas for Medical Sciences. In 2024, Dr. Sun returned to 黑料官网, where he collaborates closely with clinical colleagues to advance the clinical applications of tumor immunotherapy.

Dr. Sun leads multiple funded projects and holds several patent applications. His research has been published in over 30 high-impact journals, including The Journal of Clinical Investigation (JCI), Nature Communications, and Cancer Research. He has received numerous prestigious awards, such as the 24th Annual ECOG-ACRIN Young Investigator Award, the American Society of Hematology (ASH) Abstract Achievement Awards in 2022 and 2023, the Young Investigator Award at the 17th International Myeloma Workshop (IMW) of the International Myeloma Society, and the Scholar-in-Training Award at the AACR Annual Meeting.

• Immunotherapy
• Chimeric Antigen Receptor T Cell Therapy
• Chimeric Antigen Receptor NK Cell Therapy
• Multifunctional Antibody Therapy
• Oncolytic Virus Therapy
• Hematologic Malignancies
• Solid Tumors

Dr. Sun is dedicated to research in the field of tumor immunotherapy, particularly focusing on the development and application of novel Chimeric Antigen Receptor T Cell (CAR-T) immunotherapies. His research focuses on enhancing the therapeutic efficacy of CAR-T cells in treating relapsed and refractory tumors, as well as uncovering the molecular mechanisms underlying therapy resistance.

In addition, Dr. Sun is actively developing combinatory strategies involving CAR-T cells and oncolytic viruses to overcome the challenges associated with solid tumor treatment. He is also committed to innovating multifunctional antibody therapies, aiming to broaden the versatility of antibody-based treatments such as antibody-drug conjugates (ADCs) and bispecific antibodies.